Product Reports Resources Pricing Login Book a demo

Owkin

Biotech & Life Sciences · Paris, France · Founded 2016

Collaborative research platform and unique AI drug development solutions that make precision medicine a reality

Investors

28 investors on Owkin's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Seed 4 investors entered at this stage
NJF Capital
Shana Fisher
Jean-Paul Clozel
Nicole Junkermann
Series A 10 investors entered at this stage
Series B+ 14 investors entered at this stage
Bristol-Myers Squibb
CNRS Innovation
SISTAFUND
INRIA
OTB Ventures
Sanofi
Google for Startups Accelerator
Alpha Intelligence Capital
École normale supérieure – PSL University
Serena
French National Centre for Scientific Research - CNRS
EIT Health
Karista
PSL University

Ownership

Who owns Owkin

Estimated cap table from Dealroom's shareholder data — share of equity by holder. Stakes as last recorded by Dealroom (Mar/2026). Percentages are indicative.

27.5% Founders

Some investors are hidden on this public profile. See the full cap table on Dealroom →

Global footprint

Where Owkin has talent and traffic

Workforce by country
15 countries with
team presence
🇫🇷 France77.1%
🇬🇧 United Kingdom10.1%
🇺🇸 United States6.3%
🇩🇪 Germany2%
🇧🇪 Belgium0.7%
Top 5 of 15 shown
Web traffic by country
77K monthly visits
across markets
🇮🇳 India22.7%
🇫🇷 France12.3%
🇺🇸 United States10%
🇩🇪 Germany9%
🇬🇧 United Kingdom7.7%
Top 5 markets shown

Talent graph

The shape of Owkin's talent

Dealroom maps Owkin's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

64 standout operatorsDealroom-flagged across the org
87 AI specialistsincl. 49 core researchers
430 employees mappedperson by person
DimensionScore
AI Talentlive Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock Owkin's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$3M patent portfolio · 9 active families

Estimated portfolio value
$3M
0.29% of valuation · 13.7× smaller than top peer Caris Life Sciences ($40M)
9 active patent families
Where Owkin innovates Artificial intelligenceBiomedical engineeringConvolutionConvolutional neural networkFeature vector

Where Owkin concentrates vs peers

Each axis is a top-10 topic across Owkin and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

Owkin's 3 investments and acquisitions.

Every disclosed deal where Owkin appeared as a backer or acquirer, 2023–2026. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

3 deals across Owkin's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        02 · Portfolio market map

        Owkin's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        3 of 3 deals

        Market sentiment

        What the market is saying about Owkin

        An AI-synthesized read of the highest-engagement posts about Owkin on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Owkin on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.